AgingResearch.NewsJoin free

Phase 2Completed

A Study of CT-868 in Type 1 Diabetes Mellitus

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus

Sponsor
Carmot Therapeutics, Inc. (Industry)
Enrollment
111 enrolled
Conditions
Overweight; Obese; Type 1 Diabetes Mellitus
Interventions
CT-868; CT-868 Pen Injector; CT-868 Pen Injector, Placebo
Ages
adults, older adults
Registry
NCT06062069

Full record on ClinicalTrials.gov

From the registry

This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.

Primary outcomes

  • Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered